<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="788915" id="root" date="1997-08-08" xml:lang="en">
<title>SWEDEN: ASTRA SEES GROWTH PICKING UP LATER.</title>
<headline>ASTRA SEES GROWTH PICKING UP LATER.</headline>
<dateline>STOCKHOLM 1997-08-08</dateline>
<text>
<p>Swedish drug company Astra AB said on Friday sales growth was levelling off for the time being but would pick up later.  </p>
<p>&quot;Growth is levelling off somewhat only to pick up later,&quot; Astra's chief executive Hakan Mogren told the results news conference.</p>
<p>&quot;We are on our way to get approval for a number of significant products.&quot;</p>
<p>Mogren mentioned the blood pressure agent Atacand, which he said was in the final stages of the new European review process.</p>
<p>Regarding Europe, Mogren noted that anti-asthma drug Pulmicort and anti-ulcer agent Losec, the company's main drugs, had reached significant market share but still saw more to come.</p>
<p>&quot;We still see a possiblity for further growth with the new indications we have,&quot; he said.</p>
<p>He also pointed out that the company has increased costs for research and development (R&amp;D) in connection with projects moving from a pre-clinical stage to a clinical phase.</p>
<p>&quot;We have taken a significant step forward and taken the costs via the result,&quot; Mogren said.</p>
<p>Astra's R&amp;D expenditure in the first half rose 22 percent to 3.99 billion crowns.</p>
<p>Morgren said Astra's marketing partner in the U.S., Merck Inc, was intending to expand its field-based sales organisation during the second half of 1997.</p>
<p>&quot;We will recruit between 500 to 700 people over and above the 800 we already have,&quot; Mogren said.</p>
<p>-- Joel Dahlberg, Stockholm newsroom +46-8-700 1007</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="SWED">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="C31">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="C42">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="E41">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="ECAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="GCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
  <code code="GJOB">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-08"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-08-08"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-08-08"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="STOCKHOLM"/>
<dc element="dc.creator.location.country.name" value="SWEDEN"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
